Skip to search formSkip to main contentSkip to account menu

GSK1322322

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Bridged Bicyclo Compounds, HeterocyclicHydroxamic Acids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Reducing Antibacterial Development Risk for GSK1322322 by Exploring Potential Human Dose Regimens in Nonclinical Efficacy Studies Using Immunocompetent Rats
ABSTRACT Directly testing proposed clinical dosing regimens in nonclinical studies can reduce the risk during the development of… 
2015
2015
Frequency of Spontaneous Resistance to Peptide Deformylase Inhibitor GSK1322322 in Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Streptococcus pneumoniae
ABSTRACT The continuous emergence of multidrug-resistant pathogenic bacteria is compromising the successful treatment of serious… 
2014
2014
The Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GSK1322322 in Healthy Volunteers
GSK1322322 is the first in a new class of antibiotics that inhibit peptide deformylase, necessary for bacterial protein… 
2014
2014
Safety , Tolerability , and Efficacy of GSK 1322322 in the Treatment of Acute Bacterial Skin and Skin Structure Infections
GSK1322322 represents a new class of antibiotics that targets an essential bacterial enzyme required for protein maturation… 
2013
2013
Potent Sub-MIC Effect of GSK1322322 and Other Peptide Deformylase Inhibitors on In Vitro Growth of Staphylococcus aureus
ABSTRACT Peptide deformylase (PDF), a clinically unexploited antibacterial target, plays an essential role in protein maturation… 
2013
2013
Safety, tolerability and pharmacokinetics of repeat dosing of the antibiotic GSK1322322, a peptide deformylase inhibitor: a randomized placebo-controlled study.
OBJECTIVES GSK1322322 is a potent inhibitor of peptide deformylase, an essential bacterial enzyme required for protein maturation… 
2013
2013
Safety, tolerability, and pharmacokinetics of oral and intravenous administration of GSK1322322, a peptide deformylase inhibitor
GSK1322322 is the first in a new class of antibiotics that targets peptide deformylase (PDF), an essential bacterial enzyme… 
Review
2012
Review
2012
News in brief
The Innovative Medicines Initiative (IMI) has launched a €223 million (US$280 million) New Drugs 4 Bad Bugs (ND4BB) programme to… 
2011
2011
Determination of Disk Diffusion and MIC Quality Control Ranges for GSK1322322, a Novel Peptide Deformylase Inhibitor
ABSTRACT GSK1322322 is a novel peptide deformylase inhibitor in the early phase of development for treatment of complicated… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)